» Articles » PMID: 25230938

Stimulation of Innate Immunity by in Vivo Cyclic Di-GMP Synthesis Using Adenovirus

Overview
Date 2014 Sep 19
PMID 25230938
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The bacterial second messenger cyclic di-GMP (c-di-GMP) stimulates inflammation by initiating innate immune cell recruitment and triggering the release of proinflammatory cytokines and chemokines. These properties make c-di-GMP a promising candidate for use as a vaccine adjuvant, and numerous studies have demonstrated that administration of purified c-di-GMP with different antigens increases protection against infection in animal models. Here, we have developed a novel approach to produce c-di-GMP inside host cells as an adjuvant to exploit a host-pathogen interaction and initiate an innate immune response. We have demonstrated that c-di-GMP can be synthesized in vivo by transducing a diguanylate cyclase (DGC) gene into mammalian cells using an adenovirus serotype 5 (Ad5) vector. Expression of DGC led to the production of c-di-GMP in vitro and in vivo, and this was able to alter proinflammatory gene expression in murine tissues and increase the secretion of numerous cytokines and chemokines when administered to animals. Furthermore, coexpression of DGC modestly increased T-cell responses to a Clostridium difficile antigen expressed from an adenovirus vaccine, although no significant differences in antibody titers were observed. This adenovirus c-di-GMP delivery system offers a novel method to administer c-di-GMP as an adjuvant to stimulate innate immunity during vaccination.

Citing Articles

Stimulator of interferon genes (STING) expression in the enteric nervous system and contributions of glial STING in disease.

Dharshika C, Gonzales J, Chow A, Morales-Soto W, Gulbransen B Neurogastroenterol Motil. 2023; 35(7):e14553.

PMID: 37309618 PMC: 10266835. DOI: 10.1111/nmo.14553.


Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma.

Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B Commun Biol. 2022; 5(1):757.

PMID: 35902768 PMC: 9334280. DOI: 10.1038/s42003-022-03675-4.


Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy.

Waters C Open Biol. 2021; 11(12):210277.

PMID: 34905701 PMC: 8670957. DOI: 10.1098/rsob.210277.


Shigella flexneri Diguanylate Cyclases Regulate Virulence.

Ojha R, Dittmar A, Severin G, Koestler B J Bacteriol. 2021; 203(23):e0024221.

PMID: 34543105 PMC: 8570270. DOI: 10.1128/JB.00242-21.


The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development.

Yan H, Chen W Vaccines (Basel). 2021; 9(8).

PMID: 34452042 PMC: 8402453. DOI: 10.3390/vaccines9080917.


References
1.
Barker J, Koestler B, Carpenter V, Burdette D, Waters C, Vance R . STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio. 2013; 4(3):e00018-13. PMC: 3663186. DOI: 10.1128/mBio.00018-13. View

2.
Zandman-Goddard G, Shoenfeld Y . Infections and SLE. Autoimmunity. 2005; 38(7):473-85. DOI: 10.1080/08916930500285352. View

3.
Blaauboer S, Gabrielle V, Jin L . MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo. J Immunol. 2013; 192(1):492-502. PMC: 6195764. DOI: 10.4049/jimmunol.1301812. View

4.
Reetz J, Herchenroder O, Putzer B . Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer. Viruses. 2014; 6(4):1540-63. PMC: 4014709. DOI: 10.3390/v6041540. View

5.
Romling U, Galperin M, Gomelsky M . Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev. 2013; 77(1):1-52. PMC: 3591986. DOI: 10.1128/MMBR.00043-12. View